330 related articles for article (PubMed ID: 26543874)
1. Antitumor Responses of Invariant Natural Killer T Cells.
Altman JB; Benavides AD; Das R; Bassiri H
J Immunol Res; 2015; 2015():652875. PubMed ID: 26543874
[TBL] [Abstract][Full Text] [Related]
2. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
Front Immunol; 2018; 9():1990. PubMed ID: 30298063
[TBL] [Abstract][Full Text] [Related]
3. Roles of NKT cells in cancer immunotherapy.
Bae EA; Seo H; Kim IK; Jeon I; Kang CY
Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410
[TBL] [Abstract][Full Text] [Related]
4. Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions.
Singh AK; Gaur P; Das SN
Hum Immunol; 2014 Mar; 75(3):250-60. PubMed ID: 24373798
[TBL] [Abstract][Full Text] [Related]
5. The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.
Krijgsman D; Hokland M; Kuppen PJK
Front Immunol; 2018; 9():367. PubMed ID: 29535734
[TBL] [Abstract][Full Text] [Related]
6. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
7. Invariant natural killer T cell-based immunotherapy for cancer.
Motohashi S; Nakayama T
Immunotherapy; 2009 Jan; 1(1):73-82. PubMed ID: 20635975
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer.
Motohashi S; Okamoto Y; Yoshino I; Nakayama T
Clin Immunol; 2011 Aug; 140(2):167-76. PubMed ID: 21349771
[TBL] [Abstract][Full Text] [Related]
9. The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy.
Taniguchi M; Tashiro T; Dashtsoodol N; Hongo N; Watarai H
Int Immunol; 2010 Jan; 22(1):1-6. PubMed ID: 19858073
[TBL] [Abstract][Full Text] [Related]
10. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
[TBL] [Abstract][Full Text] [Related]
11. [Invariant NKT cell-based immunotherapy for lung cancer and head and neck cancer].
Ihara F; Motohashi S
Nihon Rinsho; 2017 Feb; 75(2):312-316. PubMed ID: 30562870
[TBL] [Abstract][Full Text] [Related]
12. Innate lymphoid cells and natural killer T cells in the gastrointestinal tract immune system.
Montalvillo E; Garrote JA; Bernardo D; Arranz E
Rev Esp Enferm Dig; 2014 May; 106(5):334-45. PubMed ID: 25287236
[TBL] [Abstract][Full Text] [Related]
13. Orchestration of invariant natural killer T cell development by E and Id proteins.
Roy S; Zhuang Y
Crit Rev Immunol; 2015; 35(1):33-48. PubMed ID: 25746046
[TBL] [Abstract][Full Text] [Related]
14. Cigarette smoke alters the invariant natural killer T cell function and may inhibit anti-tumor responses.
Hogan AE; Corrigan MA; O'Reilly V; Gaoatswe G; O'Connell J; Doherty DG; Lynch L; O'Shea D
Clin Immunol; 2011 Sep; 140(3):229-35. PubMed ID: 21684213
[TBL] [Abstract][Full Text] [Related]
15. Pathogen-expanded CD11b+ invariant NKT cells feedback inhibit T cell proliferation via membrane-bound TGF-β1.
Han Y; Jiang Z; Chen Z; Gu Y; Liu Y; Zhang X; Cao X
J Autoimmun; 2015 Apr; 58():21-35. PubMed ID: 25592391
[TBL] [Abstract][Full Text] [Related]
16. Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy.
Taniguchi M; Harada M; Dashtsoodol N; Kojo S
Proc Jpn Acad Ser B Phys Biol Sci; 2015; 91(7):292-304. PubMed ID: 26194854
[TBL] [Abstract][Full Text] [Related]
17. Invariant NKT cells as novel targets for immunotherapy in solid tumors.
Pilones KA; Aryankalayil J; Demaria S
Clin Dev Immunol; 2012; 2012():720803. PubMed ID: 23118781
[TBL] [Abstract][Full Text] [Related]
18. The regulatory role of invariant NKT cells in tumor immunity.
McEwen-Smith RM; Salio M; Cerundolo V
Cancer Immunol Res; 2015 May; 3(5):425-35. PubMed ID: 25941354
[TBL] [Abstract][Full Text] [Related]
19. Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines.
Faveeuw C; Trottein F
Cancer Res; 2014 Mar; 74(6):1632-8. PubMed ID: 24599135
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
Macho-Fernandez E; Cruz LJ; Ghinnagow R; Fontaine J; Bialecki E; Frisch B; Trottein F; Faveeuw C
J Immunol; 2014 Jul; 193(2):961-9. PubMed ID: 24913977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
